Adherex to Present at Rodman & Renshaw 8th Annual Healthcare Conference

The i-Technology Media!	Register \| Log in

.NET · AJAX · CLOUD · ECLIPSE · FLEX · OPEN WEB · iPHONE · JAVA · LINUX · OPEN SOURCE · ORACLE · PBDJ · SEARCH · SILVERLIGHT · SOA · VIRTUALIZATION · WEB 2.0 · WIRELESS · XML

Comments

Plone and Drupal: Different Approaches, Different Results

paul.nowak wrote: Matt, thanks for the comments. I made an error on the version of Plone. It's 2.5 Plone running on Zope 2.9x. In regards to the additional products, we have a skin installed and we have a product that we had custom developed for us that connects to a PostgreSQL database. We've looked at slow PostgreSQL queries causing problems and have not been able to find an issue. We've also tested for the case where the PostgreSQL server is down and have not been able to create an issue. We therefor...

Nov. 4, 2009 04:19 PM EST

Cloud Expo on Google News

Did you read today's front page stories & breaking news?

2009 East

PLATINUM SPONSORS:

IBM

Smarter Business Solutions Through Dynamic Infrastructure

IBM

Smarter Insights: How the CIO Becomes a Hero Again

Microsoft

Windows Azure

GOLD SPONSORS:

Appsense

Why VDI?

Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments

ExactTarget

Messaging in the Cloud - Email, SMS and Voice

Freedom OSS

Stairway to the Cloud

Sun

Sun's Incubation Platform: Helping Startups Serve the Enterprise

POWER PANELS:

Cloud Computing & Enterprise IT: Cost & Operational Benefits

How and Why is a Flexible IT Infrastructure the Key To the Future?

Click For 2008 West
Event Webcasts

2009 East

GOLD SPONSORS:

Get Your Transactions Under Control: SOA Performance Management

Software AG

Performance Driven Adoption: The Secret to Advancing SOA

Intel

The Evolving SOA Appliance: 3 Game-Changing Innovations

SILVER SPONSOR:

Denodo

Data Mashups: Deliver Your Project Faster with Virtualized Data Services Across Internal & External Sources

POWER PANELS:

The Business Value of Service Orientation

Driving Profitability Through User Experience

Click For 2008 West
Event Webcasts

Live Google News by SYS-CON!

Top Three Links You Must Click On

From the Wires

Adherex to Present at Rodman & Renshaw 8th Annual Healthcare Conference

Adherex to Also Host an Analyst and Investor Meeting in New York

By: Marketwire .

Nov. 3, 2006 01:11 PM

RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (MARKET WIRE) -- 11/03/06 -- Adherex Technologies Inc. (TSX: AHX)(AMEX: ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that Dr. William P. Peters, Adherex's Chairman and CEO, will be presenting at the Rodman & Renshaw 8th Annual Healthcare Conference on Monday, November 6, 2006 at 10 a.m. in the Kennedy Room of the New York Palace Hotel. The presentation will be available via live and replay Webcast at www.adherex.com.

The Company will also host an analyst and investor meeting on Wednesday, November 8, 2006, at 5 p.m. at The Westin New York at Times Square. The meeting will feature presentations on eniluracil by Dr. Robert B. Diasio, Professor, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Dr. Howard A. Burris, Director of Drug Development, Sarah Cannon Research Institute as well as presentations on ADH-1 by Dr. Douglas S. Tyler, Professor of Surgery and Chief, Section of Surgical Oncology, Duke University Medical Center and Dr. William P. Peters, Adherex's Chairman and CEO. The analyst and investor meeting will also be available via live and replay Webcast at www.adherex.com.

About Adherex Technologies

Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We aim to be a leader in developing innovative treatments that address important unmet medical needs in cancer. We currently have multiple products in the clinical stage of development, including ADH-1 (Exherin(TM)), eniluracil and sodium thiosulfate (STS). ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex is emerging as a pioneering oncology company. For more information, please visit our website at www.adherex.com.

Contacts:
Adherex Technologies Inc.
Melissa Matson
Director, Corporate Communications
919-484-8484
matsonm@adherex.com

Published Nov. 3, 2006
Copyright © 2006 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.

About Marketwire .
Copyright © 2009 Marketwire. All rights reserved. All the news releases provided by Market Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.